Tempus AI (TEM) said Thursday that it has expanded its partnership with Takeda Pharmaceutical (TAK) to support Takeda's oncology research and development using real-world multimodal datasets and biological model systems.

Financial terms of the new agreement were not provided.

Tempus AI said Takeda will use Tempus AI' real-world data and AI tools for its cancer therapeutic pipeline.

The companies have also initiated a multi-phase project using patient-derived tumor organoids linked to Tempus' genetic sequencing, aiming to improve drug candidate prioritization and effectiveness predictions, Tempus said.

Shares of Tempus were up 1.7% in recent premarket activity, while Takeda was marginally down by 0.2%.

Price: 50.16, Change: +1.01, Percent Change: +2.05